Quick Answer
INSMED Inc reported R&D Expense of $771.09 million for fiscal year 2025.
INSMED Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $771.09M | +28.9% |
| 2024 | $598.37M | +4.8% |
| 2023 | $571.01M | +43.6% |
| 2022 | $397.52M | +45.7% |
| 2021 | $272.74M | +50.6% |
| 2020 | $181.16M | +37.5% |
| 2019 | $131.71M | -9.3% |
| 2018 | $145.28M | +32.4% |
| 2017 | $109.75M | -10.6% |
| 2016 | $122.72M | +65.2% |
| 2015 | $74.28M | +31.9% |
| 2014 | $56.29M | +27.1% |
| 2013 | $44.28M | +48.7% |
| 2012 | $29.78M | +4.0% |
| 2011 | $28.62M | +508.7% |
| 2010 | $4.70M | -48.9% |
| 2009 | $9.21M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $186.41M | +23.6% | +5.2% |
| June 30, 2025 | $177.19M | +20.7% | +16.1% |
| March 31, 2025 | $152.58M | +26.0% | +1.2% |
| September 30, 2024 | $150.81M | +38.2% | +2.8% |
| June 30, 2024 | $146.75M | -25.5% | +21.2% |
| March 31, 2024 | $121.08M | -5.3% | +10.9% |
| September 30, 2023 | $109.15M | +9.3% | -44.6% |
| June 30, 2023 | $196.97M | +122.5% | +54.0% |
- INSMED Inc showed an increase of +28.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, INSMED Inc’s r&d expense has grown by 8275.1% (from $9.21 million to $771.09 million).
- The most recent figure is from INSMED Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: